Dexcom

Dexcom is a medical device company headquartered in San Diego, California, that develops continuous glucose monitoring (CGM) systems. Its technology allows users to track glucose levels continuously via sensors that transmit data to smartphones, receivers, and insulin delivery partners, reducing the need for routine fingersticks.

The company's core product line includes the G6 and G7 CGM systems, with the G7 serving as the flagship model. In 2024, Dexcom expanded its reach with the launch of Stelo, the first FDA-cleared over-the-counter glucose biosensor in the U.S. designed for adults with prediabetes and Type 2 diabetes who do not use insulin.

As a publicly traded company on the NASDAQ (DXCM), Dexcom operates at a significant scale with annual revenue of approximately $4 billion and a global workforce of roughly 9,000–10,000 employees. The company maintains strategic integrations with smartwatch ecosystems and major insulin pump and pen manufacturers.